Author(s):
Shanthi Priya DK, Mukthinuthalapati Mathrusri Annapurna
Email(s):
sdarga@gitam.in
DOI:
10.52711/0974-360X.2024.00893 
Address:
Shanthi Priya DK1,2*, Mukthinuthalapati Mathrusri Annapurna1
1Department of Pharmaceutical Analysis, GITAM School of Pharmacy, Visakhapatnam, India.
2School of Pharmacy, Anurag University, Ghatkesar, Hyderabad
*Corresponding Author
Published In:
Volume - 17,
Issue - 12,
Year - 2024
ABSTRACT:
Niraparib and Abiraterone are anti-cancer agents. A new stability indicating UPLC method has been developed and validated for the simultaneous assay of Niraparib and Abiraterone using Acquity UPLC HSS T3 Column with UV detection at 215 nm within a run time of 3 minutes where Niraparib was eluted at 1.169 min and that of Abiraterone at 0.684 min. Linearity was observed over the concentration range of 2.5-15 µg/mL for Niraparib and 12.5-75 µg/mL for Abiraterone respectively and the regression equations were found to be y=68577x+10960 and y=66848x+7064.7 for Niraparib and Abiraterone respectively. The LOD was found to be 0.32 µg/ml and 0.46 µg/ml whereas the LOQ was found to be 0.98 µg/ml and 1.38 µg/ml for Niraparib and Abiraterone respectively.
Cite this article:
Shanthi Priya DK, Mukthinuthalapati Mathrusri Annapurna. Stability indicating RP-UPLC method for the simultaneous estimation of Niraparib and Abiraterone in pharmaceutical dosage forms. Research Journal Pharmacy and Technology. 2024;17(12): 5885-9. doi: 10.52711/0974-360X.2024.00893
Cite(Electronic):
Shanthi Priya DK, Mukthinuthalapati Mathrusri Annapurna. Stability indicating RP-UPLC method for the simultaneous estimation of Niraparib and Abiraterone in pharmaceutical dosage forms. Research Journal Pharmacy and Technology. 2024;17(12): 5885-9. doi: 10.52711/0974-360X.2024.00893 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-12-30
REFERENCES:
1. Liu MC, Sutedja J and Tewari KS. Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: safety and efficacy. Expert Rev Anticancer Ther. 2021; 21(5): 475-480.
2. Ryan CJ and Cheng ML: Abiraterone acetate for the treatment of prostate cancer. Expert Opin Pharmacother. 2013; 14(1): 91-96.
3. Venu Gopal K and Sujath M. An innovative stability indicating HPLC method with impurity profiling of Niraparib-An anticancer drug in pharmaceutical formulations. Rasayan J Chem. 2022; 15(4): 2976-2983.
4. Vamseekrishna G, Ajay Kumar G, and Chowdary YA. Bioanalytical method development and validation of Niraparib in plasma samples by LC-MS/MS. Indo American Journal of Pharmaceutical Research.2017; 7(12): 1127-1135.
5. Sai G, Sridhar Mangamma K. Development and validation of bioanalytical method for estimation of Niraparib in rat plasma using high performance LC-MS/MS and its application to pharmacokinetic study. International Journal of Advances in Pharmacy and Biotechnology. 2020; 6(2): 1-8.
6. Mohan Goud V, Sandhya Rani B, Sharma JVC and Sirisha P. Development and validation for the estimation of Abiraterone acetate in bulk and pharmaceutical dosage form by UPLC. Research J Pharm and Tech. 2019; 12(6): 3029-3032.
7. Kavitapu D, Arthanareeswari M, Sudarshan M and Arockia SJ New stability indicating RP-HPLC method for the determination of Abiraterone acetate, its related substances and degradation products in bulk and dosage form. Materials Today Proceedings. 2021; 34(2): 469-478.
8. Sarwar B, Ankit K, Afzal O, Abdul M, Alfawaz A, Imran K, Fahad A, Waleed H.A, Abul MB, Kawish S, Debi Prasad P and Rahman M. Systematic development and validation of a RP-HPLC method for estimation of Abiraterone acetate and its degradation products. J Chrom Sci. 2021; 59(1): 79-87.
9. Kuna AK, Ganapaty S and Radha GV. Analytical method development and validation for the estimation of Abiraterone and its impurity in pharmaceutical formulation by RP-HPLC. Der Pharmacia Lettre. 2018; 10(9): 19-31.
10. Mathrusri Annapurna M, Debi Prasad Pradhan and Krishna Chaitanya R. Stability indicating RP-HPLC method for the determination of Abiraterone (An Anti-Cancer Drug). Research J Pharm and Tech. 2018; 11(7): 3007-3012.
11. Ramesh Babu M and Umamaheswara Rao V. Stability indicating method development and validation for the estimation of residue of Abiraterone by HPLC. Int J Pharm. 2016; 6(2): 267-276.
12. ICH Validation of analytical procedures: Text and methodology, Q2 (R1), International Conference on Harmonization. (2005).
13. ICH Q1A (R2) Stability testing of new drug substances and products. (2003).